Fair and cost-conscious allocation of omalizumab, a groundbreaking food allergy therapy.

Buckey, Timothy M; Sun, Di; Spergel, Jonathan M

Buckey, Timothy M; Sun, Di; Spergel, Jonathan M.

Afiliação

Buckey TM; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Section of Allergy and Immunology, Division of Pulmonary, Allergy, and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: timothy.buckey@pennmedicine.upenn.edu.
Sun D; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Spergel JM; Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Ann Allergy Asthma Immunol ; 133(1): 18-19, 2024 Jul.

Article em En | MEDLINE | ID: mdl-38960561

Assuntos

Antialérgicos; Hipersensibilidade Alimentar; Omalizumab; Omalizumab/uso terapêutico; Humanos; Hipersensibilidade Alimentar/tratamento farmacológico; Hipersensibilidade Alimentar/economia; Antialérgicos/uso terapêutico; Antialérgicos/economia; Análise Custo-Benefício

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antialérgicos / Omalizumab / Hipersensibilidade Alimentar Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google